{
    "nctId": "NCT00327769",
    "briefTitle": "Faslodex Advanced Breast Cancer Local Chinese Study",
    "officialTitle": "A Double Blind, Double Dummy, Randomised, Multicentre Study to Compare the Efficacy and Safety of Fulvestrant 250mg With Arimidex 1mg as a Secondary-line Therapy in the Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 234,
    "primaryOutcomeMeasure": "Time to Disease Progression (TTP)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal advanced breast cancer with oestrogen receptor positive\n* Progression under first-line anti-oestrogen therapy.\n\nExclusion Criteria:\n\n* Life-threatening metastasis; contraindication to anastrozole\n* \\>2 regimens of hormonotherapy for advanced breast cancer",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}